CRSP: CASGEVY and three late-stage assets drive growth, with pivotal data and global expansion ahead
CASGEVY’s pediatric label expansion and strong payer coverage are driving rapid revenue growth, while three key assets—CTX310, zugo-cel, and CTX611—are advancing toward pivotal trials. The pipeline is supported by robust research, AI-driven productivity, and a focus on global expansion and next-gen…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.